Skip to main content

Table 4 General information of patients and statistical summary of continuous numerical observation indexes

From: Therapeutic effect of subcutaneous injection of low dose recombinant human granulocyte-macrophage colony-stimulating factor on pulmonary alveolar proteinosis

IndexesBefore treatment VS 6 months (n = 20)Before treatment VS 12 months (n = 17)
Before treatment6 monthsP valueBefore treatment12 monthsP value
Oxygen partial pressure(mmHg)69.05 ± 1.1488.16 ± 15< 0.00167.56 ± 11.4281.25 ± 13.550.002
Alveolar-arterial oxygen partial pressure difference(mmHg)35.77 ± 16.0018.1 ± 13.690.00135.84 ± 15.5228.75 ± 12.210.220
FVC(L)3.34 ± 0.883.54 ± 0.830.0223.165 ± 0.9523.365 ± 0.8490.139
DLCO (%)69.65 ± 22.4984.49 ± 13.730.00468.75 ± 26.0289.24 ± 14.700.010
Six-minute walking distance(miles)501.9 ± 133.22645 ± 117.180.002486.0 ± 134.0624.0 ± 149.70.021
  1. FVC Forced vital capacity, DLCO Carbon monoxide diffusion capacity
  2. Pulmonary function, blood gas analysis and six-minute walking distance test results (mean ± standard deviation)